Probiomic Therapeutics™ for Eczema, Atopic Dermatitis, Eosinophilic Esophagitis (EoE), Metabolic Disorders
Sarasota, FL, September 21, 2016– Quorum Innovations has successfully isolated LfQi6 from the human host. Demonstrating strong biofilm formations. Bioactives from LfQi6 have novel bimodal biofilm modulation. Quorum Innovation’s Probiomic Therapeutics™ inhibit and detach pathogenic biofilm while enhancing commensal resident biofilm. Reducing inflammation, promoting inherent defense barriers, and immune functions by upregulating the expression of essential homeostatic protein and filaggrin in human tissue.
Quorum Innovations has demonstrated stability of the LfQi6 Probiomic TherapiesÒ in alcohol, aqueous, and lipid vehicles. Providing for a wide range of applications.
Dr. Nicholas Monsul, MD – CEO and Dr. Eva Berkes, MD – Chief Medical Officer founded Quorum Innovations in 2011. “Quorum Innovation’s new drug candidates are extracted from the human microbiome in a “vertical advance” that creates a new era in immunology by helping to overcome microbial resistance to antibiotics. Once delivered, like native human microbiota in healthy individuals, Quorum Innovation’s Probiomic TherapeuticsTM act like microbiome-based software to direct human cells to express particular proteins within target tissues. By matching the particular Probiomic TherapeuticTM to the desired protein effect in the chosen organ of interest, our new human microbiome-based therapeutics have the power to regulate human and human microbiomial physiology like no other therapeutic system today.”
Emerging research on various types of inflammation indicate direct links to many clinical conditions and a dysbiotic or abnormal microbiome. When the skin is inflamed, its barrier functions become compromised leading to conditions such as atopic dermatitis, psoriasis, acne and rosacea. This has led the pharmaceutical and personal care industries to seek better ways to prevent and address skin inflammation and chronic inflammatory disorders.
Quorum’s bio-extracts, have demonstrated proof of concept in ex-vivo, in-vitro, and initial human clinical testing. Pre-clinical and clinical models show that these bio-extracts modulate the innate immune system by rebalancing the microbiome to: 1) reduce skin inflammation as measured by IL-1a levels, 2) enhance the diversity of the protective commensal population, 3) disperse and facilitate the kill of pathogenic biofilms such as MRSA and pseudomonas, 4) prevent formation of new pathogenic biofilms, and 5) up-regulate filaggrin. This results in effective treatment with minimal systemic exposure.
Founded in 2011, Quorum Innovations, LLC (“Quorum”) is a biopharmaceutical company developing first-in-class immuno-modulators for chronic medical conditions.
# # #
If you would like more information about this topic, please contact Dirk Henson at (941) 951-0126 or email at info@quoruminnovations.com.
